

---

**Sara A Courtneidge, PhD, DSc (hc)**  
**Professor**  
**Oregon Health and Science University**

Place of birth: Shoreham-by-Sea, West Sussex, UK

Nationality: US/UK

Address: Oregon Health & Science University  
Collaborative Life Sciences Building  
2730 SW Moody Avenue  
Portland, OR 97201

Telephone: 503 346 4750

E-mail: [courtneidge@ohsu.edu](mailto:courtneidge@ohsu.edu)

---

**EDUCATION**

University of Leeds, UK

BSc (Hons) III Biochemistry 1975

National Institute for Medical Research, Mill Hill, London, UK

PhD "The recognition of influenza virus-infected cells by cytotoxic T-lymphocytes" 1978 (Advisors: Drs MJ Crumpton and JJ Skehel)

**PROFESSIONAL EXPERIENCE**

1978 - 1981: Department of Microbiology and Immunology, University of California School of Medicine, San Francisco, California, USA

Postdoctoral fellow (Advisor: Prof JM Bishop)

1982 - 1985: National Institute for Medical Research, Mill Hill, London, UK

Member of Scientific Staff

1985 – 1995: Differentiation Programme, European Molecular Biology Laboratory, Heidelberg, Germany

1985-1991 Group Leader

1991-1994 Senior Scientist (with tenure)

1994-1995 Visiting Senior Scientist

1994 – 2000: SUGEN Inc, South San Francisco, California, USA

1994-1996 Vice President, Research

1997-1999 Senior Vice President, Research

1999-2000 Chief Scientist and Senior Vice President, Research

2001 - 2005: Van Andel Research Institute, Grand Rapids, Michigan, USA

2001-2002 Deputy Director and Senior Scientific Investigator

2003-2005 Distinguished Scientific Investigator

2002 – 2005: Michigan State University, Michigan, USA

Adjunct Professor, Dept of Microbiology and Molecular Genetics

2005 – 2014: Sanford|Burnham Medical Research Institute, La Jolla, California, USA

2005- Professor

2005- Director, Tumor Microenvironment and Metastasis Program

2008- Director of Academic Affairs

2008 - : University of California, San Diego

Adjunct Professor, Department of Pharmacology

2014 - : Oregon Health and Science University

Professor, Department of Cell, Developmental and Cancer Biology

Member, Center for Spatial Systems Biomedicine

Senior Investigator, Knight Cancer Institute

2014 - : Sanford|Burnham Medical Research Institute

Adjunct Professor, Tumor Microenvironment and Metastasis Program

### **HONORS AND AWARDS**

Elected member of the European Molecular Biology Organization (1990)  
The Jubilee Lecture and Harden Medal of the British Biochemical Society (2001)  
The Feodor Lynen Lecture and Lynen Medal, Nature Biotechnology Winter Symposium (2005)  
Doctor of Science (honoris causa), The University of Leeds, UK (2006)

Keynote Address, Tyrosine Phosphorylation Conference, Cold Spring Harbor (1997)  
The Adam Neville Lecture, School of Life Sciences, University of Dundee (1999)  
The Underberg Lecture, University of Rochester Cancer Center Symposium (2004)  
Keynote Lecture, Signal Transduction 2004, Luxembourg (2004)  
Keynote Speaker, Abramson Cancer Center Symposium, University of Pennsylvania (2005)  
Plenary Session Presenter, American Association for Cancer Research Annual Meeting (2005)  
Plenary Lecture, Signaling 2011, British Biochemical Society (2011)

### **MEMBERSHIP IN PROFESSIONAL SOCIETIES**

American Association for Cancer Research  
European Molecular Biology Organization  
American Society for Biochemistry and Molecular Biology  
American Society of Cell Biology

### **ADVISORY AND REVIEW BOARD PARTICIPATION**

National Institutes of Health

Ad Hoc reviewer for NIH Special Emphasis Panels, study sections, intramural reviews (1996- )  
National Cancer Institute Breast Cancer Progress Review Group (1998)  
Translational Research Working Group, National Cancer Institute (2005-2007)  
Basic Mechanisms of Cancer Therapeutics Study Section (2007-2011) (Chair 2009-2011)  
Board of Scientific Counselors, National Cancer Institute (2012- )

American Association for Cancer Research

Strategic Planning Meeting, Think Tanks and various Prize Selection Committees (2002- )  
Board of Directors (2005-2008)  
Nominating Committee (2009-2010)  
Finance and Audit Committee (2010- )

External Advisory Board, Children's Tumor Foundation (1998- )

Scientific Advisory Board, The Forbeck Foundation (2009- )

Scientific Advisory Board, BIOS, University of Freiburg, Germany (2009- )

Scientific Advisory Board, Drug Discovery Program, Ontario Institute for Cancer Research (2010- )

Scientific Advisory Board, Los Angeles Biomedical Research Institute (2012- )

Scientific Advisory Board, CNIO - Spanish National Cancer Research Center (2012- )

Past not-for-profit advisory and review activities include: Oncology Research Site Visit, Karolinska Institute, Sweden (2000), Helmholtz Association Cancer Research Review, Germany (2002), GM Mott Prize Selection Committee, General Motors Cancer Research Foundation (2002-2003), Board of Directors, Foundation for Advanced Cancer Studies (2000- ), Scientific Advisory Board, Vanderbilt Institute of Chemical Biology (2003-2007), International Advisory Committee on Research, Alberta Cancer Research Institute (2005-2010), Scientific Advisory Board, Abramson Family Cancer Research Institute (2006-2009), Scientific Review Board, Starr Cancer Consortium (2007-2009), Scientific Review

Board, Howard Hughes Medical Institute (2008-2011), Scientific Advisory Committee, Tobacco-related Disease Research Program, CA (2008-2012)

Scientific Advisory Board, Crown Biosciences (2008- )

Past for profit advisory activities include: Kinase Advisory Board, Vertex Inc (2002-2005), Scientific Advisory Board, Ceptyr Inc (2002-2005), Scientific Advisory Board, TargeGen Inc (2004-2009)

#### **EDITORIAL BOARD MEMBERSHIP**

Genes and Development (1992- )

Cancer Cell (2002- )

Cancer Discovery (2011- )

Cancer Today (2011- )

Past editorial board duties include: Journal of Cell Biology (1988-1994), Oncogene Research (1988-1991), Cell Growth & Differentiation (1991-1999), Trends in Cell Biology (1991-1996), EMBO Journal (1995-1997), Molecular and Cellular Biology (1995-2000), Anti-Cancer Drug Design (1996-2001), Molecular Cancer Research (2005-2007), CR – an AACR sponsored consumer magazine (2005-2010), Pharmacology and Therapeutics (2010-2013)

#### **CONFERENCE ORGANIZATION**

Co-organizer, Oncogene meeting (1995)

Co-organizer, Cold Spring Harbor Conference on Protein Phosphorylation, Cell Signaling and Disease (1999, 2001, 2003, 2005, 2007, 2009)

Co-organizer, Keystone Symposium on Cancer Intervention (2001)

Program Chair, American Association for Cancer Research Annual Meeting (2003)

Co-organizer, Keystone Symposium on Molecular Targets for Cancer Therapy (2005)

Co-organizer, AACR special conference, Drugging the Cancer Genome (2006)

Co-organizer, Salk Institute Conference on Posttranslational Regulation of Cell Signaling (formerly Protein Phosphorylation and Cell Signaling) (2006, 2008, 2010, 2012)

Co-organizer, Keystone Symposium on Molecular Targets in Cancer (2007)

Program Chair, AACR-NCI-EORTC Molecular Targets Conference (2007)

Program Executive Committee Member, AACR-NCI-EORTC Molecular Targets Conference (2009)

Program Committee Member, AACR Annual Meeting (2010)

Program Chair, Molecular Therapeutics of Cancer Conference (2011)

Program Committee Member, AACR-NCI-EORTC Molecular Targets Conference (2014)

#### **RESEARCH INTERESTS**

My laboratory has studied the Src family of protein tyrosine kinases for a number of years, and we have contributed to the understanding of Src transformation, regulation, substrate selection and function. Currently our research on Src and its substrates focuses on metastasis, with particular emphasis on the role of membrane structures called invadopodia. While much of my career has been spent in not-for-profit research institutions, I also worked for six years in the biotech SUGEN, where we focused on the characterization and validation of kinases involved in driving the cancer phenotype, and generating small molecule therapeutics targeting them. I remain interested in translational research, and my current research focuses on defining novel therapeutic points of intervention.

## **PUBLICATIONS**

### **In peer-reviewed journals:**

Zweerink HJ, Courtneidge SA, Skehel JJ, Crumpton MJ & Askonas BA (1977) Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses. *Nature* 267, 354-356.

Zweerink HJ, Askonas BA, Millican D, Courtneidge SA & Skehel JJ (1977) Cytotoxic T cells to type A influenza virus; viral hemagglutinin induces A-strain specificity while infected cells confer cross-reactive cytotoxicity. *Eur J Immunol* 7, 630-635.

\*Courtneidge SA, \*Levinson AD & Bishop JM (1980) The protein encoded by the transforming gene of avian sarcoma virus (pp60<sup>src</sup>) and a homologous protein in normal cells (pp60<sup>proto-src</sup>) are associated with the plasma membrane. *Proc Nat Acad Sci USA* 77, 3783-3787.

*\*co-first authors*

Payne GS, Courtneidge SA, Crittenden LB, Fadly AM, Bishop JM & Varmus HE (1981) Analysis of avian leukosis virus DNA and RNA in bursal tumors: viral gene expression is not required for maintenance of the tumor state. *Cell* 23, 311-322.

\*Levinson AD, \*Courtneidge SA & Bishop JM (1981) Structural and functional domains of the Rous sarcoma virus transforming protein (pp60<sup>src</sup>). *Proc Nat Acad Sci USA* 78, 1624-1628.

*\*co-first authors*

Courtneidge SA & Bishop JM (1982) Transit of pp60<sup>v-src</sup> to the plasma membrane. *Proc Nat Acad Sci USA* 79, 7117-7121.

Courtneidge SA, Ralston R, Alitalo K & Bishop JM (1983) Subcellular location of an abundant substrate (p36) for tyrosine-specific protein kinases. *Mol Cell Biol* 3, 340-350.

Courtneidge SA & Smith AE (1983) Polyoma virus transforming protein associates with the product of the c-src cellular gene. *Nature* 303, 435-439.

Chen L-C, Courtneidge SA & Bishop JM (1983) Immunological phenotype of lymphomas induced by avian leukosis viruses. *Mol Cell Biol* 3, 1077-1085.

Courtneidge SA & Smith AE (1984) The complex of polyoma virus middle T antigen and pp60<sup>c-src</sup>. *EMBO J* 3, 585-591.

Magee AI & Courtneidge SA (1985) Two classes of fatty acid acylated proteins exist in eukaryotic cells. *EMBO J* 4, 1137-1144.

Courtneidge SA (1985) Activation of the pp60<sup>c-src</sup> kinase by middle T antigen or by dephosphorylation. *EMBO J* 4, 1471-1477.

Wilson JB, Hayday A, Courtneidge SA & Fried M (1986) A frameshift at a mutational hotspot in the polyoma virus early region generates two new proteins that define t-antigen functional domains. *Cell* 44, 477-487.

Courtneidge SA & Heber A (1987) An 81kD protein complexed with middle T antigen and pp60<sup>C-src</sup>: a possible phosphatidylinositol kinase. *Cell* 50, 1031-1037.

Williams RL, Courtneidge SA & Wagner EF (1988) Embryonic lethality and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene. *Cell* 52, 121-131.

Kypta RM, Hemming A & Courtneidge SA (1988) Identification and characterization of p59<sup>fyn</sup> (a *src*-like protein tyrosine kinase) in normal and polyoma virus transformed cells. *EMBO J* 7, 3837-3844.

Courtneidge SA, Read M & Fried M (1989) Cytoplasmic interaction between pp60<sup>C-src</sup> and a truncated polyoma virus middle T antigen. *Oncogene Research* 4, 75-80.

Aguzzi A, Wagner EF, Williams RL & Courtneidge SA (1990) Sympathetic hyperplasia and neuroblastomas in transgenic mice expressing polyoma middle T antigen. *New Biologist* 2, 533-543.

Kypta RM, Goldberg Y, Ulug ET & Courtneidge SA (1990) Association between the PDGF receptor and members of the *src* family of tyrosine kinases. *Cell* 62, 481-492.

Ulug ET, Hawkins PT, Hanley MR & Courtneidge SA (1990) Phosphatidylinositol metabolism in cells transformed with polyoma virus middle T antigen. *J Virol* 64, 3895-3904.

Rassoulzadegan M, Courtneidge SA, Loubière R, El Baze P & Cuzin F (1990) A variety of tumours induced by the middle T antigen of polyoma virus in a transgenic mouse family. *Oncogene* 5, 1507-1510.

Otsu M, Hiles I, Goot I, Fry MJ, Ruiz-Larrea F, Panayotou G, Thompson A, Dhand R, Hsuan J, Totty N, Smith AD, Morgan SJ, Courtneidge SA, Parker PJ & Waterfield MD (1991) Characterization of two related 85 kd proteins containing SH2 and SH3 domains that bind to receptor tyrosine kinases and polyoma virus middle T antigen/pp60<sup>C-src</sup> complexes, and associate with phosphatidylinositol 3-kinase. *Cell* 65, 91-104.

Courtneidge SA, Goutebroze L, Cartwright A, Heber A, Scherneck S & Feuteun J (1991) Identification and characterization of the hamster polyomavirus middle T antigen. *J Virol* 65, 3301-3308.

Courtneidge SA, Kypta RM, Cooper JA & Kazlauskas A (1991) PDGF receptor sequences important for binding of *src* family tyrosine kinases. *Cell Growth & Differentiation* 2, 483-486.

Ulug ET, Cartwright AJ & Courtneidge SA (1992) Characterization of the interaction of polyomavirus middle T antigen with type 2A protein phosphatase. *J Virol* 66, 1458-1467.

Hiles ID, Otsu M, Volinia S, Fry MJ, Gout I, Dhand R, Panayotou G, Ruiz-Larrea F, Thompson A, Totty NF, Hsuan JJ, Courtneidge SA, Parker PJ & Waterfield MD (1992) Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. *Cell* 70, 419-429.

Twamley GM, Kypta RM, Hall B & Courtneidge SA (1992) Association of Fyn with the activated PDGF receptor: requirements for binding and phosphorylation. *Oncogene* 7, 1893-1901.

Fry MJ, Panayotou G, Dhand R, Ruiz-Larrea F, Gout I, Nguyen O, Courtneidge SA & Waterfield MJ (1992) Purification and characterization of a phosphatidylinositol 3-kinase complex from bovine brain by using phosphopeptide affinity columns. *Biochem J* 288, 383-393.

Courtneidge SA, Dhand R, Pilat D, Twamley GT, Waterfield MD & Roussel MF (1993) Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor. *EMBO J* 12, 943-950.

Mori S, Rönstrand L, Yokote K, Engström A, Courtneidge SA, Claesson-Welsh L & Heldin C-H (1993) Identification of two juxtamembrane autophosphorylation sites in the PDGF  $\beta$ -receptor. Involvement in the interaction with Src family tyrosine kinases. *EMBO J* 12, 2257-2264.

Noble MEM, Musacchio A, Saraste M, Courtneidge SA & Wierenga RK (1993) Crystal structure of the SH3 domain in human Fyn. Comparison of the three-dimensional structures of SH3 domains in tyrosine kinases and spectrin. *EMBO J* 12, 2617-2624.

Superti-Furga G, Fumagalli S, Koegl M, Courtneidge SA & Draetta G (1993) Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. *EMBO J* 12, 2625-2634.

Twamley-Stein GM, Pepperkok R, Ansorge W & Courtneidge SA (1993) The Src family protein tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. *Proc Nat Acad Sci USA* 90, 7696-7700.

Koegl M, Goldberg Y & Courtneidge SA (1993) Generation of a temperature-sensitive cSrc. *Virology* 196, 368-371.

Dhand R, Hiles I, Panayotou G, Roche S, Fry MJ, Gout I, Totty NF, Truong O, Yonezawa K, Kasuga M, Courtneidge SA & Waterfield MD (1994) PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. *EMBO J* 13, 522-533.

Kiefer F, Anhauser I, Soriano P, Aguzzi A, Courtneidge SA & Wagner EF (1994) Endothelial cell transformation by polyomavirus middle T antigen in mice lacking Src-related kinases. *Current Biology* 4, 100-109.

Borchert TV, Mathieu M, Zeelen JP, Courtneidge SA & Wierenga RK (1994) The crystal structure of human CskSH3: structural diversity near the RT-Src and n-Src loop. *FEBS Letts* 341, 79-85.

Roche S, Dhand R, Waterfield MD & Courtneidge SA (1994) The catalytic subunit of phosphatidylinositol 3-kinase is a substrate for the activated platelet-derived growth factor receptor, but not for middle T antigen:pp60<sup>c-Src</sup> complexes. *Biochem J* 301, 703-711.

Fumagalli S, Totty NF, Hsuan J & Courtneidge SA (1994) A target for Src in mitosis. *Nature* 368, 871-874.

Koegl M, Kypta RM, Bergman M, Alitalo K & Courtneidge SA (1994) Rapid and efficient purification of SH2 domain-containing proteins: Fyn, Csk and phosphatidylinositol 3-kinase p85. *Biochem J* 302, 737-744.

Koegl M, Zlatkine P, Ley SC, Courtneidge SA & Magee AI (1994) Palmitoylation of multiple Src family kinases at a homologous N-terminal motif. *Biochem J* 303, 749-753.

Roche S, Koegl M & Courtneidge SA (1994) The phosphatidylinositol 3-kinase  $\alpha$  is required for DNA synthesis induced by some, but not all growth factors. *Proc Nat Acad Sci USA* 91, 9185-9189.

Chen Y-H, Pouyssegur J, Courtneidge SA & Obberghen-Schilling EV (1994) Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts. *J Biol Chem* 269, 27372-27377.

Roche S, Koegl M, Barone MV, Roussel MF & Courtneidge SA (1995) DNA synthesis induced by some, but not all, growth factors requires Src family protein tyrosine kinases. *Mol Cell Biol* 15, 1102-1109.

Brizuela L, Ulug ET, Jones MA & Courtneidge SA (1995) Induction of interleukin-2 transcription by the hamster polyomavirus middle T antigen: a role for Fyn in T cell signal transduction. *Eur J Immunol* 25, 385-393.

Erpel T, Superti-Furga G & Courtneidge SA (1995) Mutational analysis of the Src SH3 domain: the same residues of the ligand binding surface are important for intra-and inter-molecular interactions. *EMBO J* 14, 963-975.

Alonso G, Koegl M, Mazurenko N & Courtneidge SA (1995) Sequence requirements for binding of Src family kinases to activated growth factor receptors. *J Biol Chem* 270, 9840-9848.

Landgren E, Blume-Jensen P, Courtneidge SA & Claesson-Welsh L (1995) Fibroblast growth factor receptor-1 regulation of Src family kinases. *Oncogene* 18, 2027-2035.

Roche S, Fumagalli S & Courtneidge SA (1995) Requirement for Src family kinases in G2 for fibroblast cell division. *Science* 269, 1567-1569.

Barone MV & Courtneidge SA (1995) Myc but not Fos rescue of PDGF signalling block caused by kinase inactive Src. *Nature* 378, 509-512.

Koegl M, Courtneidge SA & Superti-Furga G (1995) Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk. *Oncogene* 11, 2317-2329.

Superti-Furga G, Jönsson K & Courtneidge SA (1996) A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases. *Nature Biotechnology* 14, 600-605.

Lock P, Fumagalli S, Polakis P, McCormick F & Courtneidge SA (1996) The human p62 cDNA encodes Sam68 and not the RasGAP-associated p62 protein. *Cell* 84, 23-24.

Erpel T, Alonso G & Courtneidge SA (1996) The Src SH3 domain is required for DNA synthesis induced by PDGF and EGF. *J Biol Chem* 271, 16807-16812.

---



Roche S, McGlade J, Jones M, Gish GP, Pawson T & Courtneidge SA (1996) Requirement of phospholipase C $\gamma$  the tyrosine phosphatase Syp, the adaptor proteins SHC and Nck for PDGF-induced DNA synthesis: evidence for the existence of Ras-dependent and Ras-independent pathways. *EMBO J* 15, 4940-4948.

Dikic I, Tokiwa G, Lev S, Courtneidge SA & Schlessinger J (1996) A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. *Nature* 383, 547-550.

Weijland A, Neubauer G, Courtneidge SA, Mann M, Wierenga RK & Superti-Furga G (1996) The purification and characterization of the catalytic domain of Src expressed in *Schizosaccharomyces pombe*. Comparison of unphosphorylated and tyrosine phosphorylated species. *Eur J Biochem* 240, 756-764.

Empereur S, Djelloul S, Di Giola Y, Bruyneel E, Mareel M, Van Hengel J, Van Roy F, Comoglio P, Courtneidge SA, Paraskeva C, Chastre E & Gespach C (1997) Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the *src* or polyoma middle T oncogenes: cooperation between *src* and HGF/Met in invasion. *Br J Cancer* 75, 241-250.

Weijland A, Williams JC, Neubauer G, Courtneidge SA, Wierenga RK & Superti-Furga G (1997) Src regulated by C-terminal phosphorylation is monomeric. *Proc Nat Acad Sci USA* 94, 3590-3595.

Hansen K, Alonso G, Courtneidge SA, Ronnstrand L & Heldin CH (1997) PDGF-induced phosphorylation of Tyr28 in the N-terminus of Fyn affects Fyn activation. *Biochem Biophys Res Commun* 241, 355-362.

Williams JC, Weijland A, Gonfloni S, Thompson A, Courtneidge SA, Superti-Furga G, & Wierenga RK (1998) The 2.35Å crystal structure of the inactivated form of chicken Src: A dynamic molecule with multiple regulatory interactions. *J Mol Biol* 274, 757-775.

Lock P, Abram CL, Gibson T & Courtneidge SA (1998) A new method for isolating tyrosine kinase substrates used to identify Fish, an SH3 and PX domain-containing protein, and Src substrate. *EMBO J* 17, 4346-4357.

Roche S, Alonso G, Kazlauskas A, Dixit VM, \*Courtneidge SA & Pandey A (1998) Src-like adaptor protein (Slap) is a negative regulator of mitogenesis. *Curr Biol* 8, 975-978.

*\*corresponding author*

Roche S, Downward J, Raynal P, Courtneidge SA (1998) A function for phosphatidylinositol 3-Kinase  $\beta$  (p85 $\alpha$ -p110 $\beta$ ) in fibroblasts during mitogenesis: Requirement for insulin-and lysophosphatidic acid-mediated signal transduction. *Mol Cell Biol* 18, 7119-29.

Blake RA, Garcia-Paramio P, Parker PJ, Courtneidge SA (1999) Src promotes PKC $\delta$  degradation. *Cell Growth & Differentiation* 10, 231-241.

Broome MA, Galisteo ML Schlessinger J & Courtneidge SA (1999) The proto-oncogene c-Cbl is a negative regulator of DNA synthesis initiated by both receptor and cytoplasmic tyrosine kinases. *Oncogene* 18, 2908-2912.

Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA & Alberts AS (2000) Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. *Molecular Cell* 5, 13-25.

Broome MA & Courtneidge SA (2000) No requirement for Src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen. *Oncogene* 19 2867-2869.

Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L & Courtneidge SA (2000) SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. *Mol Cell Biol* 20, 9018-9027.

Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA & Jove R (2001) Stat3-mediated Myc expression is required for Src transformation and PDGF-mediated mitogenesis. *Proc Nat Acad Sci USA* 98, 7319-7324.

Scaife RM, Courtneidge SA & Langdon WY (2003) The multi-adaptor proto-oncoprotein Cbl is a key regulator of Rac and actin assembly. *J Cell Sci* 116, 463-73.

Voytyuk O, Lennartsson J, Mogi A, Caruana G, Courtneidge SA, Ashman LK & Ronnstrand L (2003) Src family kinases are involved in the differential signaling from two splice forms of c-Kit. *J Biol Chem* 278, 9159-9166.

Abram CL, Seals DF, Pass I, Salinsky D, Maurer L, Roth TM & Courtneidge SA (2003) The adaptor protein Fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. *J Biol Chem* 278, 16844-16851.

Seals DF, Azucena EF Jr, Pass I, Tesfay L, Gordon R, Woodrow M, Resau JH & Courtneidge SA (2005) The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. *Cancer Cell* 7, 155-165.

Bromann PA, Korkaya H, Webb CP, Miller J, Calvin TL & Courtneidge SA (2005) Platelet-derived growth factor stimulates Src-dependent mRNA stabilization of specific early genes in fibroblasts. *J Biol Chem* 280, 10253-10263.

Gianni D, Bohl B, Courtneidge SA & Bokoch GM (2008) The involvement of the tyrosine kinase c-Src in the regulation of reactive oxygen species (ROS) generation mediated by NADPH oxidase-1 (Nox1). *Mol Biol Cell* 19, 2984-2994.

Blouw B, Seals DF, Pass I, Diaz B & Courtneidge SA (2008) A role for the podosome/invadopodia scaffold protein Tks5 in tumor growth in vivo. *Eur J Cell Biol* 87, 555-567.

Schilsky RL, Gordon G, Gilmer TM, Courtneidge SA, Matrisian LM, Grad O & Nelson WG (on behalf of the Translational Research Working Group) (2008) The Translational Research Working Group Developmental Pathway for Anti-Cancer Agents (Drugs or Biologics) *Clin Canc Res* 14, 5685-5691.

Buschman M, Bromann PA, Cejudo-Martin P, Wen F, Pass I & Courtneidge SA (2009) The novel adaptor protein Tks4 (SH3PXD2B) is required for functional podosome formation. *Mol Biol Cell*, 20, 1302-1311.

Stylli SS, I STT, Verhagen AM, Xu SS, Pass I, Courtneidge SA & Lock P (2009) Nck adaptor proteins link Src and Tks5 to invadopodia actin assembly and ECM proteolysis. *J Cell Sci* 122, 2727-2740.

Crimaldi L, Courtneidge SA & Gimona M (2009) Tks5 recruits AFAP-110, p190RhoGAP and cortactin for podosome formation. *Exp Cell Res* 315, 2581-2592.

Diaz B, Shani G, Pass I, Anderson D, Quintavalle M & Courtneidge SA (2009) Tks5-dependent, Nox-mediated generation of reactive oxygen species is necessary for invadopodia formation. *Science Signaling* 2, ra53.

Gianni D, Diaz B, Taulet N, Fowler B, \*Courtneidge SA & \*Bokoch GM. (2009) Novel p47phox-related organizers regulate localized NADPH oxidase 1 (Nox1) activity. *Science Signaling* 2, ra54.

*\*co-corresponding authors*

Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MVG, Peterson KL, Indolfi C, Catalucci D, Chen J, \*Courtneidge SA & \*Condorelli G (2009) The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. *Cell Death & Diff* 16, 1590-1598.

*\*co-corresponding authors*

Iqbal Z, Cejudo-Martin P, de Brouwer A, van der Zwaag B, Ruiz-Lozano P, Scimia MC, Lindsey JD, Weinreb R, Albrecht B, Megarbane A, Alanay Y, Ben-Neriah Z, Amenduni M, Artuso R, Veltman JA, van Beusekom E, Oudakker A, Millan J-L, Hennekam R, Hamel B, \*Courtneidge SA & van Bokhoven H (2010) Disruption of the podosome adaptor protein Tks4 (SH3PXD2B) causes the skeletal dysplasia, eye and cardiac abnormalities of Frank-Ter Haar Syndrome. *American Journal of Human Genetics* 86, 254-261.

*\*corresponding author*

Quintavalle M, Elia L, \*Condorelli G & \*Courtneidge SA (2010) MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. *J Cell Biol* 189, 13-22.

*\*co-corresponding authors*

Murphy DA, Diaz B, Bromann PA, Tsai JH, Kawakami Y, Maurer J, Stewart RA, Izpisua-Belmonte JC & Courtneidge SA (2011) A Src-Tks5 pathway is required for neural crest cell migration during embryonic development. *PLOS One* 6, e22499.

Quintavalle M, Elia L, Price JH, Heynen-Genel S & Courtneidge SA (2011) A cell-based, high content screening assay reveals activators and inhibitors of cancer cell invasion. *Science Signaling* 4, ra49.

Yoneyama T, Angata K, Bao X, Courtneidge S, Chanda SK & Fukuda M (2012) Fer kinase regulates cell migration through  $\alpha$ -dystroglycan glycosylation. *Mol Biol Cell* 23, 771-780

Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, Courtneidge SA, Knaus UG, Brat DJ, Arbiser JL & Bellamkonda RV (2012) Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. *Science Translational Medicine* 4, ra36.

Diaz B, Yuen A, Iizuka S, Higashiyama S & Courtneidge SA (2103) Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. *J Cell Biol* 201, 279-92.

Burger KL, Learman BS, Boucherle AK, Sirintrapun SJ, Isom S, Díaz B, Courtneidge SA & Seals DF (2014) Src-dependent Tks5 phosphorylation regulates invadopodia-associated invasion in prostate cancer cells. *Prostate* 74, 134-48.

Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, Hague MN, Ablack A, Carmine-Simmen K, McPherson VA, Postenka CO, Turley EA, Courtneidge SA, Chambers AF & Lewis JD. (2014) Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. *Cell Rep.* epub ahead of print.

Cejudo-Martin P, Yuen A, Vlahovich N, Lock P, \*Courtneidge SA & Diaz B (2014) Genetic disruption of the *Sh3pxd2a* gene reveals an essential role in mouse development and the existence of a novel isoform of Tks5. *PLOS One* in press.

\*corresponding author

**Solicited reviews, book chapters etc:**

Bishop JM, Courtneidge SA, Levinson AD, Oppermann H, Quintrell N, Sheiness DK, Weiss SR & Varmus HE (1979) Origin and function of avian retrovirus transforming genes. *Cold Spring Harbor Symp Quant Biol USA* 44, 919-930.

Bishop JM, Courtneidge SA, Czernilofsky AP, Levinson AD, Levintow L, Luciw P, Oppermann H, Sheiness DK, Vennstrom B & Varmus HE (1981) Viral oncogenes as pleiotropic effectors. *Genes, Chromosomes and Neoplasia (33rd Ann Symp on Fundamental Cancer Research, MD Anderson Series) (FE Arrighi, PN Rao and E Stubblefield eds)*, pp 93-103.

Smith AE, Courtneidge SA, Oostra BA, Ely BK, Harvey R & Markham A (1983) The molecular basis of transformation by polyoma virus middle-T. *Cell Biology International Reports* 7, 507-508.

Courtneidge SA, Oostra B & Smith AE (1984) Tyrosine phosphorylation and polyoma virus middle T. *Cancer Cells 2/ Oncogenes and Viral Genes. Cold Spring Harbor Laboratory*, pp123-131.

Courtneidge SA (1985) The phosphorylation of tyrosyl residues. In *The Enzymology of Post-translational Modifications of Proteins Vol. II* (R.B. Freedman and H.C. Hawkins, eds.) Academic Press, London. pp 229-271.

Courtneidge SA (1986) Transformation by polyoma virus middle T antigen. *Cancer Surveys* 5, 173-182.

Courtneidge SA, Kypta RM & Ulug ET (1988) Interactions between the middle T antigen of polyomavirus and host cell proteins. *Cold Spring Harbor Symp Quant Biol* 53, 153-160.

Courtneidge SA (1989) Further characterization of the complex of middle T antigen and pp60. *Current Topics in Microbiology and Immunology* 144, 121-128.

Koegl M & Courtneidge SA (1992) The regulation of Src activity. *Seminars in Virology* 2, 375-384.

Gabrielli F & Courtneidge SA (1992) The phosphorylation of nuclear proteins in normal and transformed cells. *Ital J Biochem* 41, 9-15.

Twamley GM, Kypta RM, Hall B & Courtneidge SA (1993) Src family tyrosine kinases and the response to platelet-derived growth factor. *Advances in Second Messenger and Phosphoprotein Research* 28, 187-194.

Courtneidge SA, Fumagalli S, Koegl M, Superti-Furga G & Twamley-Stein GM (1993) The Src family of protein tyrosine kinases: regulation and normal functions. *Development Supp*, 57-64.

Courtneidge SA (1994) Non-receptor protein tyrosine kinases. In *Frontiers in Molecular Biology: Protein Kinases*. (Ed J Woodgett) Oxford University Press pp 212-242.

Courtneidge SA (1994) Protein tyrosine kinases, with emphasis on the Src family. *Seminars in Cancer Biology* 5, 239-246.

Kiefer F, Courtneidge SA & Wagner EF (1994) Oncogenic properties of the middle T antigens of polyomaviruses. *Advances in Cancer Research* 64,125-157.

Fumagalli, S. & Courtneidge SA (1994) A mitotic function for Src? *Trends in Cell Biology* 4, 345-347.

Brizuela L, Olcese LM & Courtneidge SA (1994) Transformation by polyomavirus middle T antigens. *Seminars in Virology* 5, 381-389.

Superti-Furga G & Courtneidge SA (1995) Structure-function relationships in Src family and related protein tyrosine kinases. *BioEssays* 17, 321-330.

Courtneidge SA (1995) Src family kinases and the cell cycle. *Pezcoller Foundation Symposia* 7, 45-56.

Erpel T & Courtneidge SA (1995) Src family protein tyrosine kinases and cellular signal transduction pathways. *Curr Opin Cell Biol* 7, 176-182.

Courtneidge SA & Hall A (1996) Cell regulation. *Curr Opin Cell Biol* 8, 137-138.

Roche S & Courtneidge SA (1997) Oncogenic cytoplasmic protein tyrosine kinases. In *Oncogenes and Tumour Suppressors*. (eds G Peters & K Vousden) In *Frontiers Molecular Biology: (Oxford University Press)* 94-127.

Roche S & Courtneidge SA (1997) The use of microinjection to study signal transduction in mammalian cells. In *Microinjection and Transgenesis: Springer-Verlag (Heidelberg, New York)* 171-186.

Courtneidge SA & Hall A (1998) Cell regulation. *Curr Opin Cell Biol* 10, 157-158.

Courtneidge SA & Plowman, GD (1998) The discovery and validation of new drug targets in cancer. *Curr Opin in Biotech* 9, 632-636.

Abram CL & Courtneidge SA (2000) Src family tyrosine kinases and growth factor signaling. *Exp Cell Res* 254, 1-13.

Courtneidge SA (2002) Role of Src in signal transduction pathways. The Jubilee Lecture. *Biochem Soc Trans* 30, 11-17.

Seals DF & Courtneidge SA (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. *Genes Dev* 17, 7-30.

Courtneidge SA (2003) Isolation of novel Src substrates. *Biochem Soc Trans* 31, 25-28.

Courtneidge SA (2003) Escape from inhibition. *Nature* 422, 827-828.

Bromann PA, Korkaya H & Courtneidge SA (2004) The interplay between Src family kinases and receptor tyrosine kinases. *Oncogene* 23, 7957-7968.

Courtneidge SA, Azucena Jr EF, Pass I, Seals DF & Tesfay L (2005) The Src substrate Tks5, podosomes (invadopodia), and cancer cell invasion. *Cold Spring Harbor Quant Biol* 70, 1-6.

Courtneidge SA & Neel BG (2007) Genetic and cellular mechanisms of oncogenesis. *Curr Opin Genetics & Development* 17, 1-2.

Gimona M, Buccione R, Courtneidge SA & Linder S (2008) Assembly and biological roles of podosomes and invadopodia. *Curr Op Cell Biol* 20, 235-241.

Courtneidge SA (2008) Intracellular Signaling. *Clinical Oncology* 4<sup>th</sup> edition (Eds Abeloff, Armitage, Niederhuber, Kastan & McKenna) Chapter 2.

Cejudo-Martin P & Courtneidge SA (2011) Podosomal proteins as causes of human syndromes: a role in craniofacial development? *Genesis* 49, 209-221.

Murphy DA & Courtneidge SA (2011) The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. *Nature Reviews Mol Cell Biol* 12, 413-426.

Courtneidge SA (2012) Cell migration and invasion in human disease: the Tks adaptor proteins. *Biochem Soc Trans* 40, 129-132.

Diaz B & Courtneidge SA (2012) Redox signaling at invasive microdomains in cancer cells. *Free Radical Biology and Medicine* 52, 247-256.

Gould CM & Courtneidge SA (2014) Regulation of invadopodia by the tumor microenvironment. *Cell Adh Migr* 6, epub ahead of print.